ISSN:
1432-1440
Keywords:
Antiemetic therapy
;
Alizapride
;
Cisplatin
;
Nabilone
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Twenty nonseminomatous testicular cancer patients not pretreated with emetogenic chemotherapy were included in a crossover study of antiemetic therapy. Patients were randomly assigned to receive either nabilone (2×2 mg/day) or alizapride (3×150 mg/day) prior to beginning lowdose cisplatin chemotherapy. Patients on nabilone had significantly fewer episodes of emesis than those on alizapride (medians, 1.1 vs 2.9;p〈0.01). Nabilone was superior to alizapride in giving complete relief from nausea (medians, 65% vs 30%;p〈0.01), and was more effective in shortening the duration of nausea (medians, 1.3 h vs 5.1 h;p〈0.01); however, it caused more adverse effects. It is concluded that nabilone has greater antiemetic activity than alizapride in young patients receiving low-dose cisplatin chemotherapy. Nabilone dosage should be reduced to decrease the incidence and degree of adverse reactions while leaving the definite antiemetic activity unchanged.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01728184
